Avidity Biosciences Inc
NASDAQ:RNA
Avidity Biosciences Inc
NASDAQ:RNA
Price:
25.62 USD
-2.7%
Updated:
May 7, 2024
Section:
Relative Value
The Relative Value of one
RNA
stock under the Base Case scenario is
8.97
USD.
Compared to the current market price of 25.62 USD,
Avidity Biosciences Inc
is
Overvalued by 65%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RNA
Relative Value
Base Case
8.97
USD
Overvaluation 65%
Valuation Multiples
Multiples Across Competitors
RNA Competitors Multiples
Avidity Biosciences Inc Competitors
Avidity Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Avidity Biosciences Inc
NASDAQ:RNA
|
2.1B USD | 218.3 | -9.8 | -6.4 | -6.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
288.1B USD | 5.3 | 59.8 | 13 | 19.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162.1B USD | 5.5 | 43.1 | 18.3 | 30.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.9B USD | 8.1 | 27.4 | 22.2 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
104.8B USD | 10.7 | 29.1 | 23.2 | 24.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 169.1 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46B USD | 8.9 | -7.7 | -8.3 | -7.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.2 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
